Teva to Present at the 21st Annual Morgan Stanley Global Healthcare Conference
06 Setembro 2023 - 5:30PM
Business Wire
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today
announced that Richard Francis, Teva's President and CEO, will
present at the Morgan Stanley Global Healthcare Conference on
Monday, September 11, 2023. The presentation will begin at 8:40
A.M. Eastern Time.
To access a live webcast of the presentation, visit Teva’s
Investor Relations website at
https://ir.tevapharm.com/Events-and-Presentations.
An archived version of the webcast will be available within 24
hours after the end of the live discussion and will be accessible
for up to 90 days.
About Teva Teva Pharmaceutical Industries Ltd. (NYSE and
TASE: TEVA) has been developing and producing medicines to improve
people’s lives for more than a century. We are a global leader in
generic and innovative medicines with a portfolio consisting of
over 3,500 products in nearly every therapeutic area. Around 200
million people around the world take a Teva medicine every day and
are served by one of the largest and most complex supply chains in
the pharmaceutical industry. Along with our established presence in
generics, we have significant innovative research and operations
supporting our growing portfolio of innovative medicines and
biopharmaceutical products. Learn more at www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements This
document and the conference call, may contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, which are based on management’s current beliefs
and expectations and are subject to substantial risks and
uncertainties, both known and unknown, that could cause our future
results, performance or achievements to differ significantly from
that expressed or implied by such forward-looking statements.
Important factors that could cause or contribute to such
differences include risks relating to: our ability to successfully
compete in the marketplace; our substantial indebtedness; our
business and operations in general including: the impact of global
economic conditions and other macroeconomic developments and the
governmental and societal responses thereto; compliance, regulatory
and litigation matters; other financial and economic risks; and
other factors discussed in this press release and in our Annual
Report on Form 10-K for the year ended December 31, 2022, including
in the sections captioned "Risk Factors.” Forward-looking
statements speak only as of the date on which they are made, and we
assume no obligation to update or revise any forward-looking
statements or other information contained herein, whether as a
result of new information, future events or otherwise. You are
cautioned not to put undue reliance on these forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230906345680/en/
IR Ran Meir +1 (267) 468-4475 Yael Ashman +972 (3) 914
8262 Sanjeev Sharma +1 (973) 658 2700 PR Kelley Dougherty +1
(973) 832-2810 Eden Klein +972 (3) 906 2645
Teva Pharmaceutical Indu... (NYSE:TEVA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024